Shionogi & Co., Ltd.

2019/12/13: Shionogi Announces Results of Tender Offer for Certificate of Shares, Etc. in UMN Pharma Inc. (Securities Code: 4585) and Changes in a Subsidiary
2019/12/12: NICE AND THE SMC HAVE PUBLISHED RECOMMENDATIONS ON SHIONOGI’S MULPLEO® (LUSUTROMBOPAG), APPROVING ITS USE FOR THE TREATMENT OF SEVERE THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INVASIVE PROCEDURES
2019/12/04: Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2019/12/03: Attention deficit/hyperactivity disorder (AD/HD) therapeutic agent VYVANSE® Capsule 20mg/30mg launched in Japan
2019/11/29: Shionogi Cooperates in MHLW’s HIV/AIDS Measures Project on Establishment of New HIV Test System　- Shionogi’s commitment to providing all Shionogi colleagues with opportunities for HIV tests and awareness-raising programs -
2019/11/25: Shionogi Announces XOFLUZA® Tablets 20mg for the Treatment of Influenza A or B virus Acute Infection Launched in Taiwan.
2019/11/22: Amendments: In Association with Its Submission of an Amendment of Tender Offer Statement, Shionogi Announces: (1) Partial Amendment of Its Press Release Entitled “Shionogi Announces Commencement of Tender Offer for Certificates of Shares, Etc. in UMN Pharma Inc. (Securities Code: 4585)” and (2) Amendment of Its Corresponding Public Announcement of Commencement of Tender Offer, and Corrections
2019/11/20: 2019 SHIONOGI Integrated Report have been issued.
2019/11/15: FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated Urinary Tract Infections (cUTI) in Adult Patients with Limited or No Alternative Treatment Options
2019/11/01: Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
2019/10/31: 1st Half of Fiscal 2019Financial Results
2019/10/30: Financial Results for the Second Quarter of FY2019
2019/10/30: Shionogi Announces Commencement of Tender Offer for Certificates of Shares, Etc. in UMN Pharma Inc. (Securities Code: 8840)